Retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — research profile and the documentation US laboratories expect.
Retatrutide is a single-molecule triple agonist engaging the GIP, GLP-1, and glucagon receptors. Published Phase II data position retatrutide as one of the most metabolically active research peptides characterized to date in the Australia literature.
Mechanism
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism (energy expenditure axis)
- Fatty-acid linker enabling weekly research dosing in published studies
Research use only. 3 Diamond Labs supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
